Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer

On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.

Cholangiocarcinoma—or biliary duct cancer—affects about 8000 US patients a year. On this episode of Managed Care Cast, we bring you an excerpt of an interview with Jesper B. Andersen, PhD, associate professor and group leader at the University of Copenhagen and the Biotech Research and Innovation center at the Department of Health.

There have been 3 FDA drug approvals for drugs that treat cholangiocarcinoma, but these therapies are only for patients who have certain mutations or rearrangements, signifying an unmet need, noted Andersen. And due to the limited number of patients, clinical trials are challenging.

Andersen was a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year. He spoke after the conference with Brielle Benyon, senior editor of CURE®, a publication by MJH Life Sciences®.

You can watch the interview in its entirety on Medical World News.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify